valve

Diálisis post TAVI, una complicación grave que se hace menos frecuente

Post TAVR Dialysis: a Severe Complication Less and Less Frequent

The prevalence of pre-procedural kidney failure in patients undergoing&nbsp;transcatheter aortic valve replacement (TAVR)&nbsp;can be as high as 50 &#8211; 60% (stage 3 kidney failure or worse); it has been strongly associated with acute kidney deterioration and, ultimately, an increase of post TAVR mortality. A recent meta-analyzis of several small studies carried out in a single<a href="https://solaci.org/en/2017/08/25/post-tavr-dialysis-a-severe-complication-less-and-less-frequent/" title="Read more" >...</a>

presentaciones ProEducar

See All ProEducar José Gabay Course (Eighth Edition) Presentations

We are deeply thankful to all interventional physicians who, motivated by their great scientific and educational vocation, presented their works at the José Gabay Course and actively collaborated in training and providing updated concepts for the next generations of interventional cardiologists. Read and/or download the presentations below: &nbsp; Module&nbsp;I: Fundamentals and Basic Elements. Álvarez, José.<a href="https://solaci.org/en/2017/08/22/see-all-proeducar-jose-gabay-course-eighth-edition-presentations/" title="Read more" >...</a>

¿Cómo objetivar la fragilidad en pacientes con estenosis aórtica?

How to standardize frailty in aortic stenosis patients

Frailty is the patients diminished capacity to recover after pathological or iatrogenic processes. It has a fundamental role when considering valve replacement, be it surgical (SAVR) or transcatheter&nbsp;(TAVR). &nbsp; This was clearly observed in the PARTNER I and Core-Valve Pivotal trials, which showed that despite a 95% technical success, 2 in 5 patients showed&nbsp;poor quality<a href="https://solaci.org/en/2017/08/16/how-to-standardize-frailty-in-aortic-stenosis-patients/" title="Read more" >...</a>

La revascularización incompleta se asocia a mortalidad en el TAVI

Incomplete Revascularization Is Associated with Mortality in TAVR

Courtesy of Dr. Carlos Fava. TAVR&nbsp;has proven to be beneficial for inoperable and high-risk patients, as well as for intermediate-risk patients. However, while many comorbidities have been analyzed, the presence, severity, and impact of&nbsp;coronary disease&nbsp;has not been well studied yet. This study analyzed 1270&nbsp;patients who underwent TAVR. They presented &gt;50% lesions in a major epicardial<a href="https://solaci.org/en/2017/08/15/incomplete-revascularization-is-associated-with-mortality-in-tavr/" title="Read more" >...</a>

SOLACI-CACI 2017: Todos los ganadores

SOLACI-CACI 2017: All Winners

See the list of winners for all contests carried out as part of the last SOLACI-CACI&nbsp;2017 Congress. The names were announced on Friday, August 4th, at the Congress closing ceremony. SOLACI-CACI&nbsp;2017 Congress Best Abstract Award: Dr. Gabriel Maluenda. Title: Single Trans-Septal Access Technique for Left Atrial Intracardial Echocardiography to Guide Left Atrial Appendage Closure. &nbsp;<a href="https://solaci.org/en/2017/08/10/solaci-caci-2017-all-winners/" title="Read more" >...</a>

Doble antiagregación en TAVI, simple es mejor?

Dual Antiplatelet in TAVR: Is Single Better?

Courtesy of Dr. Agustín Vecchia. As TAVR&nbsp;is expanded to lower risk patients, complications become more relevant. As regards stroke, the PARTNER 2 and SURTAVI one year outcomes are 8.0% and 8.2% respectively. The mechanisms behind this complication have not yet been clarified and, therefore, neither have guideline recommendations in this regard (as we can tell<a href="https://solaci.org/en/2017/08/02/dual-antiplatelet-in-tavr-is-single-better/" title="Read more" >...</a>

Lotus vs Sapien 3, mecanismos diferentes con resultados similares

Lotus vs Sapien 3, different mechanisms with similar results

The new generation devices for&nbsp;transfemoral transcatheter aortic valve replacement have been optimized to improve valve position and reduce residual aortic regurgitation. &nbsp; This study compared 30 day, 12 month and 24 month outcomes of the repositionable, Lotus&nbsp;valve, with controlled mechanical expansion, and the balloon-expandable valve&nbsp;Edwards Sapien 3. &nbsp; Primary end point was all cause mortality<a href="https://solaci.org/en/2017/07/26/lotus-vs-sapien-3-different-mechanisms-with-similar-results/" title="Read more" >...</a>

¿Cómo clasificar la estenosis aórtica de los pacientes que recibieron TAVI?

How can we classify aortic stenosis in patients who underwent TAVR?

Courtesy of Dr. Carlos&nbsp;Fava. Aortic stenosis&nbsp;can present different hemodynamic patterns, such as low flow and low gradient with reduced or preserved ventricular function. However, evidence on the evolution of different hemodynamic patterns after&nbsp;transcatheter aortic valve replacement (TAVR)&nbsp;is limited. This study consisted in a retrospective analysis of 368&nbsp;patients who underwent TAVR. The population was divided in<a href="https://solaci.org/en/2017/07/26/how-can-we-classify-aortic-stenosis-in-patients-who-underwent-tavr/" title="Read more" >...</a>

El aumento de la experiencia de los operadores mejora los resultados en el TAVI

Increasing operator experience improves TAVR outcomes

The introduction of transcatheter aortic valve replacement (TAVR) into clinical practice in the United States has been a tightly controlled process aimed at optimizing patient outcomes and minimizing the learning curve. Many strategies have been used to reach a rational dispersion for this new technology, including choosing sites with enough volume, and adequate operator training<a href="https://solaci.org/en/2017/07/26/increasing-operator-experience-improves-tavr-outcomes/" title="Read more" >...</a>

CRM vs DES: ¿Cuál se asocia mejor calidad de vida a largo plazo?

MRS vs. DES: Which one is associated with better long-term quality of life?

The SYNTAX (Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery) trial, which included patients with 3-vessel or left main coronary artery lesions, showed that&nbsp;myocardial revascularization surgery (MRS) turned out to be superior to&nbsp;angioplasty&nbsp;with&nbsp;drug-eluting stents (DES), mainly due to differences in&nbsp;acute myocardial infarction&nbsp;and repeat revascularization. Up to this work, patient sensations (which can be<a href="https://solaci.org/en/2017/07/21/mrs-vs-des-which-one-is-associated-with-better-long-term-quality-of-life/" title="Read more" >...</a>

Top